Nebulized BROVANA® (arformoterol tartrate) Inhalation Solution is FDA-approved for the long-term, twice-daily (morning and evening) treatment of COPD in adults.
In clinical studies, BROVANA was shown to improve lung function for up to 12 hours at a time.*
People in clinical studies reported that they used their rescue inhalers less often when taking BROVANA.
*In 2 clinical studies, 1456 adults with COPD who had similar breathing capacities measured by forced exhale over 1 second (forced expiratory volume in 1 second, or FEV1) were evaluated. The five most commonly reported side effects of BROVANA were chest or back pain, diarrhea, sinus congestion, headache, and tremor. Other reported side effects included nervousness, leg cramps, high blood potassium, shortness of breath, rash, fever, increased white blood cells, vomiting, tiredness, leg swelling, and chest congestion or bronchitis.
BROVANA has been approved for COPD only and is NOT indicated for the treatment of asthma. People with asthma who take long-acting beta2-adrenergic agonist (LABA) medicines such as BROVANA have an increased risk of death from asthma problems. It is not known if LABA medicines, such as BROVANA, increase the risk of death in people with COPD.
Get emergency medical care if your breathing problems worsen quickly, you need to use your rescue medication more often than usual, or your rescue medication does not work as well to relieve your symptoms.
Answering these questions can help you and your doctor determine how well your COPD treatment plan is working.PLAN YOUR DISCUSSION